Synthetic biology company Synthorx is laying plans for an initial public offering to raise money to advance its suite of enhanced cytokine drugs.
The San Diego-based company says it wants to use the proceeds to put its lead product candidate, an investigational cancer therapy that’s based on the drug interleukin-2 (IL-2), through dose escalation and expansion trials, and to develop products based on the same compound to treat autoimmune disorders.
It has now set a preliminary $100 million IPO target in documents filed with securities regulators Tuesday. The company has applied for a listing on the Nasdaq exchange under the stock… Read more »
UNDERWRITERS AND PARTNERS